Compare Davita Inc (DVA) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Synopsys, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Synopsys, Inc. trades at $503.05 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 8.4× Davita Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Synopsys, Inc. for 71 Days on average.
| DVA | SNPS | |
|---|---|---|
Market Cap | $11.29B | $95.39B |
Volume | 582,204 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $240.96 | $534.56 |
52-Week Low | $103.87 | $367.70 |
Typical Hold Time | 113 Days | 71 Days |
Enterprise Value | $24.01B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, but maintains strong bullish momentum with recent AI-driven partnerships and earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5%, supported by a 72.38% gross margin. Technical indicators show bullish moving averages but overbought RSI levels above 89, with key support at $500 and resistance at $505. Recent announcements with OpenAI and Amazon have driven significant investor optimism and price target upgrades.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus target suggesting 14% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks include high valuation (P/E 87.7) and execution challenges in large-scale partnerships. The stock's proximity to all-time highs requires careful monitoring of earnings delivery and competitive pressures in the EDA market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
